OxyPrem AG, a pioneering company committed to enhancing neonatal care, has successfully raised an impressive $2.3 million in its latest funding round. Specializing in the development, design, and manufacturing of advanced sensor solutions for brain oxygen monitoring of newborns, OxyPrem's innovative technologies are poised to significantly improve outcomes for the most vulnerable patient population. By providing clinicians with real-time, reliable data on brain oxygen levels, OxyPrem empowers healthcare providers to make informed decisions that can prevent dire consequences such as disabilities and cognitive impairments in premature infants. The newly acquired funding will be instrumental in further advancing OxyPrem's research and development efforts, accelerating the deployment of their cutting-edge sensors in hospitals across the globe. This injection of capital will enable the company to enhance its product offerings, expand into new markets, and ultimately help save lives and improve the quality of care for newborns at risk of hypoxic conditions. OxyPrem AG is grateful for the continued support from investors who share its vision of a future where advanced technology plays a critical role in enhancing health outcomes for infants and families. With this funding, OxyPrem is enthusiastic about paving the way for groundbreaking advancements in neonatal monitoring, ensuring that every newborn receives the vital care they need to thrive.








